new value of vaccines
TRANSCRIPT
The GSK Value Offer
The Value of Vaccines
AWA
/GE
N/0001/14
2
With the Patient’s
best interest in
mind
Classic Brands
Vaccines
Branded Generics
Through Our Broad Portfolio of Products
We support you in providing the best value for the patient
Vaccines: the story so far
“With the exception of safe water, no other modality, not even antibiotics, has had such a major effect on mortality reduction...”
Plotkin S et al,Vaccines, 20111
Vaccines
Every year up to 3 million deaths are prevented and 750,000 children are saved from disabilities through vaccination2
What vaccination can achieve
• Globally:• Approximately 700,000 deaths caused by
pneumococcal disease could be prevented by 20158
• Cases of polio are down by over 99% - from over 300,000 per year in 1988 to less than 2,000 in 20099
• Some countries have witnessed declines in hospitalisations due to rotavirus infection of up to 80%10
• Vaccination and screening can bring down the burden of cervical cancer 11
• GlaxoSmithKline has vaccines in all these disease areas
• For over 50 years we have supplied polio vaccines for elimination and eradication efforts worldwide20
• Our pneumococcal conjugate vaccine (PCV) Synflorix™i was the first PCV to receive WHO ‘prequalification’ for global use
• RotarixTM has been included in government vaccination programmes for newborn babies in many countries.. Worldwide more than 100 million doses of RotarixTM have been distributed globally, the vast majority to Least Developed Countries20
i. SynflorixTM is a registered trade mark of the GlaxoSmithKline group of companies
ii. RotarixTM is a registered trade mark of the GlaxoSmithKline group of companies
GSK playing its part
Providing access to GSK vaccines
• In 2010, we delivered 1.4 billion vaccines doses to 179 countries worldwide19
•Up to 70% of our volumes are distributed in low and middle income countries19
•GSK has a tiered pricing policy to enable pricing to be aligned to a country’s ability to pay19
•The price for UN’s Least Developed Countries list should not exceed 25%* of the western European average21
* In very isolated cases existing contractual agreements with supranational organisations such as PAHO or GAVI may mean a higher figure than 25%
OUR COLLECTIVE CHALLENGE
“A vaccine that sitson the shelfis useless”
- Albert Sabin
Beyond The Antigen Support
Cold Chain Support Access & Advocacy
Patient information Leaflets/Videos
Disease AwarenessMaterials
Vaccination RecordCards
Capacity Building
House of Vaccines
GSK’s Support Beyond The Antigen
– Based on previous experience, GSK provides support to facilitate an effective vaccination experience:– Cold chain management– Social mobilization / Overcoming barriers to
vaccination– Vaccinator training
– GSK’ vast implementation knowledge ensures to make the most of a vaccine introduction program– Community– Hospital
• Decades of experience in vaccine introduction
• Localized & “bottom-up”: Relying on local knowledge
• Learnings from other countries and vaccines are leveraged
• On-going implementation monitoring and clinical surveillance
Value of holistic support
13
Childhood Vaccination Cards - New
14
15
DISEASE AWARENESS POSTERS
MENCEVAX ACWY
Hepatitis B
Hepatitis A
Measles, Mumps & Rubella
Chicken Pox
Meningococcal Meningitis
Rotavirus Gastroenteritis
Cervical Cancer
GSK HOUSE OF VACCINES – Protecting. Human. Kind
Invasive Pneumococcal Disease, Pneumonia & Otitis Media
Chicken Pox, Measles, Mumps & Rubella
Meningococcal Meningitis
Thank you
Why vaccinate against cervical cancer using Cervarix
Relying on the right choice
Cervical Cancer Vaccination Value Offer
Worldwide cervical cancer kills one
woman every two minutes1
Cervarix is dedicated to prevent Cervical Cancer
Cervarix from GSK offers values beyond the antigen
Cervical cancer is the second biggest cause of female cancer mortality
worldwide2
References:1. Ferlay J et al. Globocan 2002. IARC 20042. WHO initiative for vaccine research3. TBC
Persistent HPV infection is the necessary cause of Cervical Cancer
• All Women are at Risk of Oncogenic HPV throughout their Lives
Cervarix is dedicated to prevent Cervical
Cancer
High efficacy: ~100% for 16/18 and93% across all types
Lehtinen et al. Lancet Oncol 2012;13:89-99
Cervarix has a good safety and tolerability
profile
Cervarix – the appropriate choice for Cervical Cancer Protection
Cervarix has been licensed with a 2 dose schedule for girls 9-14
years
Cervarix from GSK offers values beyond the antigen
Efficacy of HPV vaccines
Overall vaccine efficacy
Efficacy against HPV 16/18
Efficacy against non-vaccine
oncogenic types
= +
Efficacy of HPV vaccines
Overall vaccine efficacy
Efficacy against HPV 16/18
Efficacy against non-vaccine
oncogenic types
= +
PATRICIA: Efficacy results against high grade lesions associated with HPV 16/18
1. Lehtinen M, et al. Lancet Oncol 2012; 13:89–99; 2. Paavonen J, et al. Lancet 2009; 374:301–314..
Endpoint Group N n Vaccine efficacy, %(95% CI)
CIN2+ Vaccine 5,466 1
99.0 (94.2–100.0)Control 5,452 97
CIN3+ Vaccine 5,466 0
100.0 (85.5–100.0)Control 5,452 27
TVC-naïve cohort
End-of-study analysis1
Approximateto young women before
sexual debut: ≥ 1 dose
Efficacy beyond HPV types 16 and 18
AWA/CER/0003/14
Efficacy of HPV vaccines
Overall vaccine efficacy
Efficacy against HPV 16/18
Efficacy against non-vaccine
oncogenic types
= +
– Estimated worldwide prevalence of HPV 16/18 in high-grade lesions (CIN2/3) is 51%2
TVC-naïve
1 Lehtinen M, et al. Lancet Oncol. 2012 Jan;13(1):89-99; 2. WHO/ICO Information Centre on Human papilloma Virus (HPV) and Cervical Cancer. Available at: http:www..hpvcentre.net/dataquery (accessed Jan 2014) ;
EndpointVaccine
casesN = 5,466
Control cases
N = 5,452
Efficacy, % 95% CI
CIN2+ irrespective of DNA in the lesion † 61 172 64.9 52.7–74.2
CIN3+ irrespective of DNA in the lesion 3 44 93.2 78.9–98.7
End of study analysis1
Approximateto young women before
sexual debut: ≥ 1 dose
PATRICIA: Efficacy results against high grade lesions irrespective of HPV type
DOSAGE
– AGED 9 – 14 YEARS OLD
– If flexibility in schedule is necessary, the 2nd dose can be given between 5 and 12 months after the 1st dose. If the 2nd dose is given before month 5, then a 3rd dose must be given.
– AGED15 YEARS AND OLDER
DOSE 1 DOSE 2
0 month 1 2 3 4 5 6 months
DOSE 1 DOSE 2 DOSE 3
0 month 1 month 2 3 4 5 6 months
If flexibility in schedule is necessary, the 2nd dose can be given between 1 and 2.5 monthsafter the 1st dose, and the 3rd dose between 5 and 12 months after the 1st dose.1
Cervarix. Summary of Product Characteristics. January 2014AWA/CER/0003/14
AWA
/CE
R/0003/14
Cervarix® Vaccine Pooled Studies: Safety Analysis
Descamps D, et al. Hum Vaccin 2009; 5:1–9.
SAE = severe adverse event.
Pooled clinical trial data analysis
(29,953 girls and women 10 to 72 years)
The most common adverse reaction was injection site pain: the majority were mild to moderate severity and were not long lasting
Fatigue, headache and myalgia were the most common solicited general symptoms
No significant increase in relative risk of potential autoimmune events detected in meta-analysis
Similar overall rates of pregnancy outcomes
AWA
/CE
R/0003/14
Further information
– Full Prescribing Information For Cervarix® Vaccine Is Available Upon Request
– For Safety Information Or For Reporting Any Adverse Event
Associated With GSK Products,
Kindly Call GSK 24-hours Dedicated Toll Free Line
0800CALLGSK (08002255475 )
THANK YOU
THANK YOU